Navigation Links
Rigel Announces First Quarter 2012 Financial Results
Date:5/1/2012

SOUTH SAN FRANCISCO, Calif., May 1, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2012.

For the first quarter of 2012, Rigel reported a net loss of $23.2 million, or $0.32 per share, compared to a net loss of $20.8 million, or $0.40 per share, in the first quarter of 2011. Weighted average shares outstanding for the first quarters of 2012 and 2011 were 71.4 million and 52.3 million, respectively.

Contract revenue from collaborations in the first quarter of 2012 was comprised of a $750,000 payment from Daiichi Sankyo related to Rigel's existing collaboration agreement with them.  This payment relates to an oncology compound in pre-clinical testing at Daiichi Sankyo. There was no contract revenue from collaborations reported in the first quarter of 2011.

Rigel reported total operating expenses of $24.1 million in the first quarter of 2012, compared to $20.9 million in the first quarter of 2011. The increase in operating expenses was primarily due to the increase in research and development expenses in Rigel's clinical research programs.  The largest increase was related to R343, an inhaled SYK inhibitor for asthma, that is expected to commence a Phase 2 clinical trial this summer.

As of March 31, 2012, Rigel had cash, cash equivalents and available for sale securities of $223.3 million, compared to $247.6 million as of December 31, 2011.  Rigel expects to end 2012 with cash, cash equivalents and available for sale securities in excess of $140.0 million, which is expected to be sufficient to fund operations into 2014.

"We are very pleased with the pace and strength of Rigel's product development as progress continues in our three active clinical programs, and as we prepare to initiate Phase 2 studies in both asthma and dis
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
2. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
5. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
6. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
7. Rigels R788 Phase 2a Results Published in Arthritis and Rheumatism
8. Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results
9. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
10. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
11. Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... 25, 2014 Nanomix Inc., (Nanomix), ... development of mobile diagnostic tests to enable ... and pre-hospital settings, today announced it has ... The certification was awarded by the British ... leading certification bodies. ISO ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2
(Date:11/27/2014)... knows, Cyber Monday is a crazy shopping day. Owing to ... now providing many big promotions on its website. Customers can ... current prices. The discount are up to 80% off. So ... orders above $88) from Dec. 1 – 4 2014. , ... are willing to shop on the internet. As a leading ...
(Date:11/27/2014)... 28, 2014 This is a professional ... global Bronchoscopes industry with a focus on the Chinese ... status of the Bronchoscopes manufacturers and is a valuable ... interested in the industry. , Firstly, the report provides ... applications and manufacturing technology. Then, the report explores the ...
(Date:11/27/2014)... November 27, 2014 Absolute PhysioCare ... recently announced that its personalized treatment plans, highly ... can help victims of sports injuries reach pre-injury ... or patellofemoral pain syndrome, Absolute Physio has the ... jumper’s knee, ACL tears, meniscal injuries, groin strain ...
(Date:11/27/2014)... 2014 Blood-borne pathogens raise the risk ... and procedures in place to counter this. However, it ... things tainted with menstrual blood are taken as seriously. ... more sanitary way to handle tampons and menstrual pads ... Sonora, Calif. , He then created a prototype of ...
(Date:11/27/2014)... -- Most babies and young children don,t need medicines ... Drug Administration says. Over-the-counter (OTC) cold and cough ... 2 because they could cause serious and potentially deadly ... about three colds a year, but children get them ... want to give them pain relievers, decongestants and other ...
Breaking Medicine News(10 mins):Health News:Tidebuy.com Launching Overcoats Sales for the Special Monday in 2014 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:Coquitlam Physiotherapy Clinic Now Helps Clients Reach Pre-Injury State 2Health News:Steer Clear of Cold Meds for Babies, FDA Advises 2
... link, experts say , , TUESDAY, May 27 (HealthDay News) ... day: A new study finds that gum disease could raise ... disease had a 14 percent higher risk of cancer than ... persisted among never smokers," said lead researcher Dominique Michaud, a ...
... D for children is 200 International Units (IUs), but ... safely take ten-times that amount. According to a recently ... Endocrinology & Metabolism (JCEM), this order-of-magnitude increase could improve ... other long-term health benefits. , Our research reveals that ...
... at Seattle Children,s Hospital, Swedish Medical Center and Medical University of South ... ... Ranging from Pediatrics to Cancer ... NEW YORK, May 27 The Doctor,s Channel, (http://www.thedoctorschannel.com ), hailed by ...
... Present on Communicating the Value of ... in Clinical Drug Development, MOUNTAIN VIEW, Calif., ... a leading provider of software, strategic,consulting, and regulatory ... Helen Kastrissios, Ph.D., senior,scientist, Pharsight Strategic Consulting Services, ...
... a partnership between Peninsula Medical School, NHS South ... has been awarded a 20 million grant to ... including heart disease, diabetes, mental illness, childhood disability ... of seven new collaborations between NHS organisations and ...
... available worldwide, WASHINGTON, May 27 ... Schoomaker today announced continued expansion of medical,information ... record,led by the Army. Medical Communications for ... capabilities and access to battlefield medical,information via ...
Cached Medicine News:Health News:Gum Disease Might Boost Cancer Risk 2Health News:Gum Disease Might Boost Cancer Risk 3Health News:Current vitamin D recommendations fraction of safe, perhaps essential levels for children 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 2Health News:The Doctor's Channel Launches New Videos from Three Top Hospitals 3Health News:Pharsight Invited to Present on Modeling and Simulation at ARCS Australia Scientific Congress 2Health News:£20M health research collaboration announced for the southwest England 2Health News:Life-Saving Technology Expands Globally to Military Branches - Transforming the Way Medical Care is Documented on the Battlefield 2
... System is a sterile, pre-shaped, three-dimensional device ... a mesh cylinder to a circular underlay ... unique and innovative design combines the three ... in the repair of inguinal hernias. ,Its ...
... The 800 Series KTP/YAG Surgical Laser ... market. It is a high-power, dual-wavelength ... plastic surgery, orthopedics, general surgery, neurosurgery, ... KTP/532 beam surgically cuts, vaporizes and ...
... a new, portable, light weight, high power ... cosmetic and plastic surgery, general surgery, ENT ... resurfacing, it is the smallest, yet among ... market. It provides an ideal treatment for ...
... Venus-i™ Laser System is a new, portable, ... with applications in dermatology, cosmetic and plastic ... ideal laser for skin resurfacing, it is ... Erbium:YAG lasers on the market. It provides ...
Medicine Products: